Optimising the Management of Ventilated Patients and Quality of Life in Motor Neurone Disease: a Pilot Study

Study Purpose:

This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group.

Study Status:

Not yet recruiting


Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Study Type:


Type of Intervention:


Intervention Name:

Telemonitoring via Careportal®





Study Chair(s)/Principal Investigator(s):

Robert M Angus, MRCP, FRCP, Liverpool University Hospitals NHS Foundation Trust

Clinicaltrials.gov ID:


Neals Affiliated?


Coordinating Center Contact Information

Hikari Ando, PhD / email hidden; JavaScript is required / 0151529

Full Study Summary:

This study will test the feasibility of previously developed Telehealth system, using a device called Careportal®, to monitor people with MND/ALS who are using non-invasive ventilation (NIV). The Careportal® is a CE marked portable tablet computer device allowing telecommunication between patients and their care team through bespoke question sets, overnight oximetry test, and patient-ventilator interaction(PVI) data. Previously, the weekly telemonitoring via Careportal® was found to be an effective method to monitor symptom changes, allowing clinicians to optimise the care of ventilated patients with MND. This study will assess the practicality of using Careportal® in the care of ventilated patients with MND by monitoring patients through a patient support call centre. The call centre will screen the data and liaise with appropriate clinicians regarding changes of symptoms.

Study Sponsor:

Liverpool University Hospitals NHS Foundation Trust

Estimated Enrollment:


Estimated Study Start Date:

04 / 25 / 2022

Estimated Study Completion Date:

12 / 31 / 2022

Posting Last Modified Date:

03 / 29 / 2022

Date Study Added to neals.org:

03 / 29 / 2022

Minimum Age:

18 Years

Maximum Age:


Inclusion Criteria (Patients):

- Confirmed diagnosis of MND with respiratory muscle weakness

- Adults who are capable of informed consent

- Patients for whom we anticipate survival of 6 months or more

- Able to communicate with an interviewer. Alternative communication methods will be used as required in order to mitigate communication difficulties.

Exclusion Criteria (Patients):

- Patients who have declined NIV